期刊文献+

紫杉醇周疗同步放疗治疗复发转移乳腺癌 被引量:2

Concurrent chemoradiotherapy with weekly Paclitaxol in advanced breast cancer
下载PDF
导出
摘要 目的 探讨伴有压迫症状的脑转移或骨转移且合并内脏转移的晚期乳腺癌合理的治疗模式.方法 化疗方案均为单药紫杉醇80mg/m2 d1,d8、d15,21天为1周期.全脑放疗采用高能X线全脑对穿照射,总量分别为45Gy和40Gy.骨放疗采用X线外照射,总量分别为33Gy和40Gy.放化疗同步进行.临床疗效评定按WHO实体瘤疗效评定标准.每完成2个周期化疗进行一次疗效评价.结果 4例患者总体疗效评价均为PR,神经系统压迫症状及骨痛症状均得到缓解,TTP分别为9个月、5个月、6+个月和8.5个月.结论 采用同步放化疗治疗有压迫症状的脑转移或骨转移且合并内脏转移的晚期乳腺癌,可以有效缓解症状、改善生存质量. Objective. To investigate the treatment pattern in patients with visceral organ metastatic breast cancer who having symotoms of brain or bone metastasis involved. Method The total dose of whole - brain radiotherapy were 45 Gy and 40 Gy, respectively. Ther bone radiotherapy were 33 Gy and 40 Gy, respectively. At the same timelehemolherapy were given with Paclitaxol 80 mg/m2,dl ,8,15, every 21 days as one cycle. The efficacy was evaluated every 2 cycles of chemotherapy according to WHO standard. Result The objective efficacy of 4 patifts were PR, The constricts symptoms of the CNS and pain of the bone were relieved. TTP of 4 patients were 9,5,6 + and 8.5 months, respectively. Conclusion Treatment pattern of concurrent chemoradiotherapy in visceral organ metastatic patients with having symptoms of brain or bone metastasis result in a effectiveness to reduce symptoms and improve QOL.
出处 《实用肿瘤学杂志》 CAS 2011年第5期437-438,共2页 Practical Oncology Journal
关键词 晚期乳腺癌 同步治疗 化疗 放疗 Advanced breast cancer Concurrent chemoradiotherapy Chemotherapy Radiotherapy
  • 相关文献

参考文献3

二级参考文献22

  • 1Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev, 2001, 27:165-176.
  • 2Johnson JR, Williams G, Pazdur R, et al. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol, 2003, 21 : 1404-1411.
  • 3Kinnane N. Burden of bone disease. Eur J Oncol Nuts, 2007, 11 Suppl 2 : S28-31.
  • 4Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med, 2005, 35:84-99.
  • 5Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol, 2007, 25: 1423-1436.
  • 6Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oneology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oneol, 2003, 21:4042-4057.
  • 7Weitnnan R, Sauter N, Eriksen EF, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006. Crit Rev Oncol Hematol, 2007, 62:148-152.
  • 8Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J CIin Oncol, 2005, 23:4925-4935.
  • 9Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer, 2003, 89:2031-2037.
  • 10Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase Ⅱ trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oneol, 2006, 24:4895-4900.

共引文献260

同被引文献17

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部